Replies to post #213677 on Biotech Values

[Rocky3]

Re $ABBV and $GILD - Interesting article about pricing and inclusion in PBM plans:

http://nu-retail.com/mavyret/

[DewDiligence]

ENTA—Mavyret scripts for week ending 9/18/17 (from IMS)…

TRx: 282, +52% from prior week
NRx: 225, +44% from prior week

The above week-over-week growth rates may be slightly inflated insofar as the week ending 9/8/17 included Labor Day.

As previously noted, Mavyret’s absolute script numbers reported by IMS are low because IMS misses much of the public sector of the HCV market that ABBV is targeting.